OncLive TV

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses outcomes for patients with anaplastic large-cell lymphoma.

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses MALT1 as a potential target for patients with activated B cell-like diffuse large B-cell lymphoma.

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms.

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

James C. Yao, MD, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the analysis of the linked SEER-Medicare database in patients with neuroendocrine tumors.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the greater exposure to high-quality healthcare that is provided by the integration of ancillary services into community urology practices.

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.